Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences

Abstract

Author's summary It is common practice that most countries follow western cardiovascular (CV) treatment guidelines from major clinical trials mainly including Caucasians. Recent researches indicate racial differences in intrinsic thrombogenicity and response to antithrombotic agents. Thrombogenic property is closely related to atheroma progression and clinical manifestation of atherothrombotic events, with African Americans trending toward the most thrombogenic state and East Asians having the lowest thrombogenic milieu. The time has come to develop the “thrombogenicity-tailored CV treatment strategy” based on specific biomarkers or functional assays. Future studies should focus on establishing a particular footprint of these properties for achieving maximum net clinical benefits.

Real-World Management of Pharmacological Thromboprophylactic Strategies for COVID-19 Patients in Japan

“…Actually, previous studies reported that East Asian patients could reduce anti-ischemic benefits and increase bleeding risk during antithrombotic therapies compared with Caucasian patients. 23 , 24 …”

The current status and outcomes of in-hospital P2Y12 receptor inhibitor switching in Korean patients with acute myocardial infarction

“…[Epub ahead of print] tent P2Y12RIs still had a high bleeding tendency in Korean patients with AMI. Since East Asians have the lowest thrombogenicity compared to other races, East Asian patients with cardiovascular disease have reduced anti-ischemic benefits and elevated bleeding risk with antithrombotic therapy, including potent P2Y12RIs, compared to Caucasian patients [21]. In addition, although the effect of reducing ischemic events of potent P2Y12RIs was significant in the early phase after PCI when compared to clopidogrel, the risk of bleeding was continuously and gradually increasing during the maintenance phase of DAPT [22].…”

Percutaneous Patent Foramen Ovale Closure After Stroke

“…Optimal patient selection for PFO closure may require further research on the ethnic difference in thrombogenicity and response to oral antithrombotic therapy. 24) 25) In the distant future, we will also have to discuss PFO closure for primary prevention in some selected patients.…”